IL15RA
Interleukin-15 receptor subunit alpha
As of the edition of 20 October 2026, IL15RA (interleukin-15 receptor subunit alpha, UniProt Q13261) has 4 drugs tested at it and 4 companies on the list, 0 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q13261
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- In more than one place
- Solved structures
- 4
- Disease areas
- Cancer; Blood and lymph; Immune system; Lungs and airways; Urinary and reproductive; Infections; Pregnancy and women's health; Heart and blood vessels
- Registered trials of its drugs
- 38
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 2 |
| Stopped | 1 |
| Total | 4 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Nogapendekin alfa inbakicept | Marketed | Phase 3 | Ends 2036 |
| Recombinant human interleukin-15 | Stopped | Phase 2 | none listed |
| FL115 | Active | Phase 2 | none listed |
| XmAb24306 | Active | Phase 1 | none listed |
4 of 4 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Engaged | 2 |
| Undetermined | 2 |
| Total on the list | 4 |